Document Library
Click the icons below to search through Pioneer’s reports and documents.
- 340B Drug Discounts: An Increasingly Dysfunctional Federal Program (35819)
- An Act advancing health care research and decision-making centered on patients and people with disabilities (16928)
- An “Impending Tsunami” in Mortality from Traditional Diseases? (11216)
- Antimicrobial Resistance: Learning from the current global health crisis to prevent another one (10226)
- Are Drug Prices Driving Healthcare Cost Growth? (22555)
- Comments on How Pharmacy Benefit Managers (PBMs) affect Smaller Pharmacies and Consumers (ID FTC-2022-0015-0001) (16367)
- Five Reasons Why Drug Rebates Are Harmful to Patients and to the Healthcare System (11591)
- Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER) (16454)
- Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies (781)
- Quality Adjusted Life Years (QALY): The Threat to Older Americans (10065)
- Testimony Against Price Control Legislation (15721)
- The Legality of QALY under the ADA (12243)
- The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector (10313)
- The QALY and Cancer Treatments: An Ill-Advised Match (10324)
- Transparency in Retail Drug Prices: Easy to Obtain but Accuracy May Be Doubtful (15675)
- Will New England See Lower Prices from Drug Pricing Transparency Legislation? (23223)